19544 results
-
List item
Veterinary medicine European public assessment report (EPAR): Equilis Te
tetanus toxoid, Horses
Date of authorisation: 08/07/2005, Revision: 8, Authorised, Last updated: 15/02/2021Authorised Adjuvanted vaccine against tetanus Overview Equilis … horses from six months of age against tetanus to prevent mortality … apart. To retain protection against tetanus, horses need to be … -
List item
Orphan designation: Toll-like receptor 4 agonist for: Treatment of osteosarcoma
Date of designation: 10/08/2022, Positive, Last updated: 15/12/2022Toll-like receptor 4 agonist Overview This medicine was … medicine intended for use against a rare condition. The medicine … Toll-like receptor (TLR4) agonist formulated in liposome, meaning … -
List item
Orphan designation: human monoclonal antibody against activin A for: Treatment of fibrodysplasia ossificans progressiva
Date of designation: 18/11/2016, Positive, Last updated: 07/10/2021human monoclonal antibody against activin A Overview On 18 … medicine intended for use against a rare condition. The medicine … human monoclonal antibody against activin A (also known as … -
List item
Orphan designation: Chimeric monoclonal antibody against claudin 6 for: Treatment of ovarian cancer
Date of designation: 24/01/2013, Withdrawn, Last updated: 08/04/2021Chimeric monoclonal antibody against claudin 6 Overview On 24 … to Ganymed Pharmaceuticals AG, Germany, for chimeric monoclonal … chimeric monoclonal antibody against claudin 6 for the treatment … -
List item
Orphan designation: human monoclonal antibody against CD4 for: Treatment of cutaneous T-cell lymphoma
Date of designation: 14/04/2004, Positive, Last updated: 10/03/2011human monoclonal antibody against CD4 Overview On 14 April … human monoclonal antibody against CD4 for the treatment of … most often occurs in people aged between 40 and 60. It is … -
List item
Orphan designation: Human monoclonal antibody against human interleukin 13 for: Treatment of eosinophilic oesophagitis
Date of designation: 13/11/2013, Withdrawn, Last updated: 30/08/2022Human monoclonal antibody against human interleukin 13 Overview … medicine intended for use against a rare condition. The medicine … human monoclonal antibody against human interleukin 13 for … -
List item
Orphan designation: Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1 for: Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa
Date of designation: 28/01/2010, Withdrawn, Last updated: 03/02/2021Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1 … 4HB ● United Kingdom An agency of the European Union … © European Medicines Agency, 2021. Reproduction is authorised … -
List item
Orphan designation: Humanised monoclonal antibody against myostatin (domagrozumab) for: Treatment of Duchenne muscular dystrophy
Date of designation: 08/02/2013, Withdrawn, Last updated: 23/10/2020Humanised monoclonal antibody against myostatin (domagrozumab … humanised monoclonal antibody against myostatin for the treatment … usually starts before the age of six years. The muscle … -
List item
Orphan designation: Human monoclonal antibody against Fas ligand for: Treatment of pemphigus
Date of designation: 09/02/2012, Positive, Last updated: 11/06/2020Human monoclonal antibody against Fas ligand Overview On 9 … human monoclonal antibody against Fas ligand for the treatment … human monoclonal antibody against Fas ligand might be of significant … -
List item
Orphan designation: Humanised IgG4 monoclonal antibody against extracellular tau for: Treatment of progressive supranuclear palsy
Date of designation: 28/07/2015, Positive, Last updated: 29/04/2019IgG4 monoclonal antibody against extracellular tau Overview … IgG4 monoclonal antibody against extracellular tau for the … usually starts in people aged over 60 years and gradually … -
List item
Orphan designation: Recombinant human minibody against complement component C5 for: Treatment of atypical haemolytic uraemic syndrome (aHUS)
Date of designation: 22/09/2008, Withdrawn, Last updated: 12/04/2019Recombinant human minibody against complement component C5 Overview … recombinant human minibody against complement component C5 for … Recombinant human minibody against complement component C5 is … -
List item
Orphan designation: Recombinant human minibody against complement component C5 for: Treatment of primary membranoproliferative glomerulonephritis
Date of designation: 27/10/2011, Withdrawn, Last updated: 12/04/2019Recombinant human minibody against complement component C5 Overview … recombinant human minibody against complement component C5 for … infusion and antiplatelet agents. Patients developing end-stage … -
List item
Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab) for: Treatment of neuroblastoma
Date of designation: 21/06/2011, Withdrawn, Last updated: 21/02/2019Chimeric monoclonal antibody against GD2 (dinutuximab) Overview … chimeric monoclonal antibody against GD2 for the treatment of … Chimeric monoclonal antibody against GD2 was authorised in the … -
List item
Orphan designation: Humanised IgG1 monoclonal antibody against human eotaxin-2 for: Treatment of systemic sclerosis
Date of designation: 19/11/2014, Positive, Last updated: 15/08/2016IgG1 monoclonal antibody against human eotaxin-2 Overview … IgG1 monoclonal antibody against human eotaxin-2 for the treatment … IgG1 monoclonal antibody against human eotaxin-2 have been … -
List item
Orphan designation: Antisense oligonucleotide directed against TGF-β2 mRNA for: Prevention of scarring post glaucoma filtration surgery
Date of designation: 19/06/2015, Positive, Last updated: 27/07/2015oligonucleotide directed against TGF-β2 mRNA Overview On … oligonucleotide directed against TGF-β2 mRNA for the prevention … inside the eye to build up again. Scarring post glaucoma filtration … -
List item
Orphan designation: Chimeric monoclonal antibody against kappa myeloma antigen for: Treatment of multiple myeloma
Date of designation: 22/05/2012, Withdrawn, Last updated: 08/06/2015Chimeric monoclonal antibody against kappa myeloma antigen Overview … chimeric monoclonal antibody against kappa myeloma antigen for … Chimeric monoclonal antibody against kappa myeloma antigen for … -
List item
Orphan designation: Human monoclonal antibody against HLA-DR for: Treatment of chronic lymphocytic leukaemia
Date of designation: 24/01/2006, Withdrawn, Last updated: 29/07/2008Human monoclonal antibody against HLA-DR Overview Please note … Commission to GPC Biotech AG, Germany, for human monoclonal … human monoclonal antibody against HLA-DR for the treatment … -
List item
Orphan designation: Human monoclonal antibody against HLA-DR for: Treatment of multiple myeloma
Date of designation: 28/02/2006, Withdrawn, Last updated: 29/07/2008Human monoclonal antibody against HLA-DR Overview Please note … Commission to GPC Biotech AG, Germany, for human monoclonal … human monoclonal antibody against HLA-DR for the treatment … -
List item
Orphan designation: Human monoclonal antibody against HLA-DR for: Treatment of Hodgkin's lymphoma
Date of designation: 16/06/2005, Withdrawn, Last updated: 29/07/2008Human monoclonal antibody against HLA-DR Overview Please note … Commission to GPC Biotech AG, Germany, for human monoclonal … human monoclonal antibody against HLA-DR for the treatment … -
List item
Orphan designation: Humanised agonistic anti-CD28 monoclonal antibody for: Treatment of B-cell chronic lymphocytic leukaemia
Date of designation: 11/04/2005, Positive, Last updated: 01/07/2005Humanised agonistic anti-CD28 monoclonal antibody … European Commission to TeGenero AG, Germany, for humanised agonistic anti-CD28 monoclonal antibody … rare in people under the age of 40. Bcell chronic lymphocytic … -
List item
Orphan designation: Human IgG1 monoclonal antibody against alpha-synuclein for: Treatment of multiple system atrophy
Date of designation: 20/05/2021, Positive, Last updated: 17/03/2022IgG1 monoclonal antibody against alpha-synuclein Overview … medicine intended for use against a rare condition. The medicine … an abnormal way and create aggregates inside cells. These … -
List item
Orphan designation: Human IgG1 monoclonal antibody against sortilin for: Treatment of frontotemporal dementia
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022IgG1 monoclonal antibody against sortilin Overview This medicine … medicine intended for use against a rare condition. The medicine … ● The Netherlands An agency of the European Union … -
List item
Orphan designation: Humanised IgG2 monoclonal antibody against TNFSF13 for: Treatment of primary IgA nephropathy
Date of designation: 21/06/2021, Positive, Last updated: 11/05/2022IgG2 monoclonal antibody against TNFSF13 Overview This medicine … medicine intended for use against a rare condition. The medicine … ● The Netherlands An agency of the European Union … -
List item
Orphan designation: Human IgG4k monoclonal antibody against CD89 for: Treatment of linear IgA bullous dermatosis (new)
Date of designation: 11/10/2022, Positive, Last updated: 24/01/2023IgG4k monoclonal antibody against CD89 … ● The Netherlands An agency of the European Union … © European Medicines Agency, 2022. Reproduction is authorised … -
List item
Orphan designation: Humanised IgG1K monoclonal antibody against interferon beta for: Treatment of dermatomyositis
Date of designation: 06/01/2021, Positive, Last updated: 18/05/2021IgG1K monoclonal antibody against interferon beta Overview … IgG1K monoclonal antibody against interferon beta (also known … www.ema.europa.eu/how-to-find-us An agency of the European Union Send …